Michael Tuchman, MD
Neurology · Palm Beach Gardens, FLNPI 1396822144
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,156 of the $28,002 with a category attached, or 93.4%. Biogen accounts for 93.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $15,363 and has fallen 99.1% since, to $139 in 2025.
Across 27 payments — averaging $1037.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$26K
- Eisai Inc.$1K
- Novartis$533
- Lilly USA, LLC$60
- AbbVie$40
- C2n Diagnostics, LLC$33
- plus $24 from 1 others
Across 575 payments — averaging $8177.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$2.6M
- Eli Lilly$762K
- Biogen$492K
- Novartis$299K
- Novo Nordisk AS$292K
- Merck$105K
- plus $184K from 5 others
What the payments were for
- Consulting fees$26,15693%
- Travel & lodging$1,1064%
- Food & beverage$7393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 5 | $26,156 |
| Eisai Inc. | 10 | $1,156 |
| Novartis | 5 | $533 |
| Lilly USA, LLC | 2 | $60 |
| AbbVie(2 entities) | 2 | $40 |
| C2n Diagnostics, LLC | 2 | $33 |
| Pfizer | 1 | $24 |
How this compares
$28,002 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 47 | $921 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 43 | $651 |
| Bupropion Hcl | 14 | $591 |
| Primidone | 12 | $561 |
| Quetiapine Fumarate | 31 | $542 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 11 | $308 |
Paid to pharmacies, not to this prescriber.
Other neurology in Palm Beach Gardens
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.